SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	220,985	322,807	239,700	104,060	225,922	59,333
Short-Term Investments	1,618	1,682	1,418	201,394	108,417	328,657
Cash & Short-Term Investments	222,603	324,489	241,118	305,454	334,339	387,991
Cash Growth	-22.29%	34.58%	-21.06%	-8.64%	-13.83%	371.01%
Accounts Receivable	181,241	173,819	111,001	63,506	55,883	8,563
Other Receivables	920.59	433.79	2,641	2,945	1,477	3,990
Receivables	182,162	174,253	113,642	66,451	57,360	12,553
Inventory	107,931	111,679	102,525	90,920	51,933	23,040
Prepaid Expenses	43,895	30,125	25,898	18,734	20,964	10,920
Other Current Assets	19,531	10,825	5,538	6,366	6,622	99.95
Total Current Assets	576,122	651,371	488,722	487,925	471,219	434,603
Property, Plant & Equipment	58,391	43,932	47,753	20,350	22,938	24,233
Long-Term Investments	71,609	91,439	104,091	99,959	107,665	6,849
Goodwill	1,560	1,691	3,392	-	-	-
Other Intangible Assets	6,581	8,875	14,542	17,181	18,900	19,695
Long-Term Deferred Tax Assets	209,023	206,400	44,723	29,641	18,919	11,837
Long-Term Deferred Charges	21,162	21,963	9,090	-	-	-
Other Long-Term Assets	8,341	11,059	10,771	9,107	3,985	3,025
Total Assets	952,818	1,036,811	723,171	664,241	643,652	500,241
Accounts Payable	2,545	3,403	2,346	23,106	16,931	8,954
Accrued Expenses	60,343	79,653	71,331	55,035	64,776	36,543
Short-Term Debt	-	50,000	50,000	-	-	-
Current Portion of Long-Term Debt	25,000	100,715	-0	-	-	-
Current Portion of Leases	8,025	7,091	7,061	5,644	5,481	4,906
Current Income Taxes Payable	3,011	451.82	88.78	208.36	1,997	-
Other Current Liabilities	164,265	154,962	110,792	79,079	59,120	20,193
Total Current Liabilities	263,189	396,276	241,619	163,073	148,306	70,595
Long-Term Debt	-	-	94,484	143,722	-	-
Long-Term Leases	41,965	26,676	26,505	6,530	10,256	13,572
Long-Term Deferred Tax Liabilities	-	-	1,909	-	-	-
Other Long-Term Liabilities	33,594	39,874	37,703	34,356	40,850	36,915
Total Liabilities	338,748	462,827	402,219	347,681	199,465	121,175
Common Stock	39,157	39,157	39,157	39,157	39,157	39,157
Additional Paid-In Capital	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848
Retained Earnings	-565,313	-621,532	-861,561	-827,555	-689,141	-746,951
Comprehensive Income & Other	36,546	43,800	21,243	20,112	9,325	2,013
Total Common Equity	595,237	546,273	283,686	316,560	444,187	379,067
Minority Interest	18,833	27,711	37,265	-	-	-
Shareholders' Equity	614,070	573,984	320,951	316,560	444,187	379,067
Total Liabilities & Equity	952,818	1,036,811	723,171	664,241	643,652	500,241
Total Debt	74,989	184,482	178,050	155,896	15,738	18,478
Net Cash (Debt)	147,614	140,007	63,068	149,558	318,602	369,513
Net Cash Growth	84.02%	121.99%	-57.83%	-53.06%	-13.78%	-
Net Cash Per Share	1884.91	1787.78	805.33	1909.74	4068.30	5148.87
Filing Date Shares Outstanding	78.31	78.31	78.31	78.31	78.31	78.31
Total Common Shares Outstanding	78.31	78.31	78.31	78.31	78.31	78.31
Working Capital	312,934	255,095	247,104	324,852	322,914	364,007
Book Value Per Share	7600.72	6975.49	3622.46	4042.23	5671.93	4840.39
Tangible Book Value	587,096	535,708	265,752	299,380	425,288	359,371
Tangible Book Value Per Share	7496.76	6840.58	3393.45	3822.85	5430.60	4588.90
Buildings	-	-	-	-	-	159.12
Machinery	31,262	32,717	30,611	21,078	19,165	18,238
Construction In Progress	585.07	201.95	236.84	1,643	1,276	375.64

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.